BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 8104468)

  • 1. The decanoates of flupenthixol and clopenthixol in the treatment of chronic schizophrenic in-patients. Implications for community psychiatry.
    Martyns-Yellowe IS
    West Afr J Med; 1993; 12(2):110-3. PubMed ID: 8104468
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A double-blind comparative trial of the decanoates of clopenthixol and fluphenazine in the treatment of chronic schizophrenic out-patients.
    Walker CA
    Pharmatherapeutica; 1983; 3(5):289-93. PubMed ID: 6133287
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Depot flupenthixol decanoate for schizophrenia or other similar psychotic disorders.
    Quraishi S; David A
    Cochrane Database Syst Rev; 2000; (2):CD001470. PubMed ID: 10796442
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-acting injectable risperidone: safety and efficacy in stable patients switched from conventional depot antipsychotics.
    Turner M; Eerdekens E; Jacko M; Eerdekens M
    Int Clin Psychopharmacol; 2004 Jul; 19(4):241-9. PubMed ID: 15201572
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clopenthixol and flupenthixol depot preparations in outpatient schizophrenics. I. A one year double-blind study of clopenthixol decanoate and flupenthixol palmitate.
    Dencker SJ; Lepp M; Malm U
    Acta Psychiatr Scand Suppl; 1980; 279():10-28. PubMed ID: 6931470
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Flupenthixol decanoate (fluanxol depot) in the treatment of chronic schizophrenic patients.
    Haider I
    J Pak Med Assoc; 1985 Sep; 35(9):286-9. PubMed ID: 3934417
    [No Abstract]   [Full Text] [Related]  

  • 7. A 5-year follow-up study of chronic schizophrenics treated with clopenthixol decanoate.
    Carney MW
    Pharmatherapeutica; 1984; 4(1):57-63. PubMed ID: 6150493
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Chemotherapy with neuroleptics. Clinical and pharmacokinetic aspects with a particular view to depot preparations.
    Knudsen P
    Acta Psychiatr Scand Suppl; 1985; 322():51-75. PubMed ID: 2866666
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A comparative trial of depot pipothiazine.
    Steinert J; Neder A; Erba E; Pugh CR; Robinson C; Priest RG
    J Int Med Res; 1986; 14(2):72-7. PubMed ID: 2870944
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparative double-blind study of flupenthixol decanoate and fluphenazine decanoate in the treatment of patients relapsing in a schizophrenic symptomatology.
    Wistedt B; Ranta J
    Acta Psychiatr Scand; 1983 Jun; 67(6):378-88. PubMed ID: 6349256
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The positive and negative symptoms of schizophrenia: patterns of response to depot neuroleptic treatment.
    Martyns-Yellowe IS
    West Afr J Med; 1994; 13(4):200-3. PubMed ID: 7756183
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [A 1-year experience with the administration of clopenthixol decanoate in schizophrenic psychoses].
    Svestka J; Náhunek K; Cesková E; Rysánek R
    Cesk Psychiatr; 1984 Jun; 80(3):146-54. PubMed ID: 6148152
    [No Abstract]   [Full Text] [Related]  

  • 13. Clopenthixol and flupenthixol depot preparations in outpatient schizophrenics. II. Factor analysis of the CPRS sub-scale for schizophrenia.
    Dencker SJ; Frankenberg K; Hansen V; Malm U
    Acta Psychiatr Scand Suppl; 1980; 279():29-40. PubMed ID: 6931471
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clopenthixol and flupenthixol depot preparations in outpatient schizophrenics. IV. Serum levels and clinical outcome.
    Dencker SJ; Malm U; Jørgensen A; Overø KF
    Acta Psychiatr Scand Suppl; 1980; 279():55-63. PubMed ID: 6931473
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Haloperidol decanoate and flupenthixol decanoate in schizophrenia. A long-term double-blind cross-over comparison.
    Eberhard G; Hellbom E
    Acta Psychiatr Scand; 1986 Sep; 74(3):255-62. PubMed ID: 3788652
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combining depot antipsychotic with an assertive monitoring programme for treating first-episode schizophrenia in a resource-constrained setting.
    Chiliza B; Ojagbemi A; Esan O; Asmal L; Oosthuizen P; Kidd M; Gureje O; Emsley R
    Early Interv Psychiatry; 2016 Feb; 10(1):54-62. PubMed ID: 24690088
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The effects of a 50% reduction of cis(z)-flupenthixol decanoate in chronic schizophrenic patients maintained on a high dose regime.
    Cookson IB
    Int Clin Psychopharmacol; 1987 Apr; 2(2):141-9. PubMed ID: 3298419
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Double-blind comparison of half-dose and standard-dose flupenthixol decanoate in the maintenance treatment of stabilised out-patients with schizophrenia.
    Johnson DA; Ludlow JM; Street K; Taylor RD
    Br J Psychiatry; 1987 Nov; 151():634-8. PubMed ID: 3446307
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clopenthixol decanoate in schizophrenia.
    Carney MW; Rutherford P
    Curr Med Res Opin; 1981; 7(4):205-11. PubMed ID: 6112116
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Do schizophrenics well adapted in the community need neuroleptics? A depot neuroleptic withdrawal study.
    Dencker SJ; Lepp M; Malm U
    Acta Psychiatr Scand Suppl; 1980; 279():64-76. PubMed ID: 6105763
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.